Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
Rhea-AI Summary
Sangamo Therapeutics (Nasdaq: SGMO) will present three abstracts at the 29th ASGCT Annual Meeting, May 11-15, 2026, in Boston and virtually. Presentations highlight neurology pipeline advances in zinc finger epigenetic regulation and updates on the protein-guided MINT modular integrase platform.
Two posters cover zinc finger repressors for Nav1.7 (small fiber neuropathy) and a BBB-penetrant prion protein repressor (nonhuman primate single-cell data). An oral presentation details modular integrase improvements at the TRAC locus and potential integration of large DNA payloads for diverse mutations.
Positive
- None.
Negative
- None.
News Market Reaction – SGMO
In the Apr 30 session, SGMO declined 10.24%, reflecting a significant negative market reaction. Argus tracked a peak move of +31.5% during that session. Argus tracked a trough of -11.0% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Listing downgrade | Negative | -33.9% | Transition from Nasdaq to OTCQB after minimum bid price non-compliance notice. |
| Mar 30 | Earnings & update | Negative | -19.7% | Reported FY25 net loss and limited cash runway alongside business highlights. |
| Mar 19 | Earnings call notice | Neutral | -2.7% | Announcement of timing and access details for Q4 and FY25 earnings call. |
| Mar 9 | BLA advancement | Positive | +8.7% | Progress on rolling BLA for ST-920 in Fabry disease with supportive eGFR data. |
| Feb 3 | Clinical data update | Positive | -7.6% | Detailed STAAR study data and initiation of rolling BLA under Accelerated Approval. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows multiple negative price reactions, including to operational and financing updates, with occasional positive responses to regulatory progress.
Over the past few months, Sangamo has combined regulatory and scientific progress with significant listing and financing pressures. A Feb 3 Fabry STAAR data update and a Mar 9 BLA advancement highlighted positive eGFR outcomes and an accelerated approval path. However, Mar 30 earnings showed a $122.9M FY25 net loss and limited cash runway, and an Apr 29 move to OTCQB following Nasdaq minimum bid non-compliance weighed heavily on the stock. Today’s ASGCT pipeline presentations fit into this neurology and genome engineering focus.
Key Terms
zinc finger epigenetic regulation medical
modular integrase technology medical
zinc finger repressors medical
epigenetic regulation medical
chronic neuropathic pain medical
prion disease medical
bbb-penetrant medical
genome editing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format. Presentations will highlight the progression of Sangamo’s neurology pipeline, including advances in zinc finger epigenetic regulation and developments in modular integrase technology.
“ASGCT is an important forum for showcasing innovation in gene and cell therapy, and we look forward to presenting advances in our neurology pipeline, alongside the strength of our genome engineering platform,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “These data will demonstrate the potency, versatility and specificity of our neurology epigenetic regulation capabilities, as well as the promise of our MINT platform to integrate large DNA payloads into the genome – an approach that may expand the possibilities for treating complex diseases.”
Presentations at the ASGCT Annual Meeting include two posters detailing Sangamo’s advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets – specifically in chronic neuropathic pain and in prion disease. A platform presentation will showcase updated data from Sangamo’s protein-guided MINT platform as an approach to integrate large sequences of DNA into the genome to potentially treat, with a single medicine, many different patients who have unique mutations in the same gene. The MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings.
ASGCT Annual Meeting Presentations and Invited Sessions
Neurology Epigenetic Regulation
- ST-503 nonclinical safety studies evaluating zinc finger repressors regulating the expression of the Nav1.7 gene for treatment of small fiber neuropathy
- Abstract No. 1309
- Poster Presentation – Tuesday, May 12, 5:00-6:30pm EDT
- Single-cell characterization of ST-506, a BBB-penetrant epigenetic repressor of Prion protein expression, in the nonhuman primate brain
- Abstract No. 1469
- Poster Presentation – Tuesday, May 12, 5:00-6:30pm EDT
Next-Generation Genome Engineering
- Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus
- Abstract No. 105
- Oral Presentation – Tuesday, May 12, 4:00-4:15pm EDT
- Session Name: Next-generation platforms for precise therapeutic genome editing and integration
All abstracts for the ASGCT Annual Meeting are available on ASGCT’s website.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to Sangamo’s technologies, the presentation of data from various therapeutic and research programs and the potential of these programs to demonstrate therapeutic benefit and transform the lives of patients. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the research and development process, including the results of clinical trials; the regulatory approval process for product candidates; and the potential for technological developments that obviate technologies used by Sangamo. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2025. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
Investor Relations and Media Inquiries
Louise Wilkie
ir@sangamo.com
media@sangamo.com
